Martha Demski Net Worth

The estimated Net Worth of Martha J Demski is at least $221 Tysiąc dollars as of 10 May 2023. Ms. Demski owns over 18,000 units of Chimerix Inc stock worth over $61,967 and over the last 20 years she sold CMRX stock worth over $10,340. In addition, she makes $148,194 as Independent Chairman of the Board at Chimerix Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Ms. Demski CMRX stock SEC Form 4 insiders trading

Martha has made over 25 trades of the Chimerix Inc stock since 2015, according to the Form 4 filled with the SEC. Most recently she bought 18,000 units of CMRX stock worth $19,980 on 10 May 2023.

The largest trade she's ever made was buying 18,000 units of Chimerix Inc stock on 10 May 2023 worth over $19,980. On average, Martha trades about 2,370 units every 54 days since 2004. As of 10 May 2023 she still owns at least 72,055 units of Chimerix Inc stock.

You can see the complete history of Ms. Demski stock trades at the bottom of the page.

Martha Demski biography

Martha J. Demski is an Independent Chairman of the Board of the Company. From August 2011 to May 2017, Ms. Demski served as Senior Vice President and Chief Financial Officer of Ajinomoto Althea, Inc. (now known as Ajinomoto Bio-Pharma Services), a fully-integrated contract development and manufacturing organization. From July 2008 to December 2010, Ms. Demski served as the Interim Chief Operating Officer and Chief Financial Officer of the Sidney Kimmel Cancer Center (SKCC), a non-profit corporation that was engaged in biomedical research. Previously, Ms. Demski served as Vice President and Chief Financial Officer of Vical Incorporated, a biotech company from December 1988 to June 2004. Ms. Demski currently serves on the board of directors and chairs the audit committee and is a member of the compensation committee of Adamas Pharmaceuticals, Inc., and Equillium, Inc., both publicly-traded biopharmaceutical companies. Prior to 2018, Ms. Demski was a member of the board of Neothetics, Inc. Ms. Demski is a National Association of Corporate Directors Board Governance Fellow. In 2017, she received the Director of the Year in Corporate Governance award by the Corporate Directors Forum. Additionally, Ms. Demski has over 13 years of banking experience with Bank of America. Ms. Demski earned a B.A. from Michigan State University and M.B.A. from The University of Chicago Booth School of Business with concentrations in accounting and finance. Our Board of Directors believes that Ms. Demski’s more than 30 years’ experience in the fields of finance and biotechnology as well as her experience as a member of various boards of directors qualifies her to serve on our Board of Directors.

What is the salary of Martha Demski?

As the Independent Chairman of the Board of Chimerix Inc, the total compensation of Martha Demski at Chimerix Inc is $148,194. There are 6 executives at Chimerix Inc getting paid more, with Michael Sherman having the highest compensation of $2,644,630.

How old is Martha Demski?

Martha Demski is 67, she's been the Independent Chairman of the Board of Chimerix Inc since 2018. There are 3 older and 9 younger executives at Chimerix Inc. The oldest executive at Chimerix Inc is Catherine Gilliss, 71, who is the Independent Director.

What's Martha Demski's mailing address?

Martha's mailing address filed with the SEC is C/O CHIMERIX, INC., 2505 MERIDIAN PARKWAY, SUITE 100, DURHAM, NC, 27713.

Insiders trading at Chimerix Inc

Over the last 12 years, insiders at Chimerix Inc have traded over $133,441,183 worth of Chimerix Inc stock and bought 1,129,869 units worth $4,757,752 . The most active insiders traders include Patrick Machado, Pharmaceuticals, Inc. Cantex oraz Ernest Mario. On average, Chimerix Inc executives and independent directors trade stock every 25 days with the average trade being worth of $72,060. The most recent stock trade was executed by Michael T. Andriole on 8 August 2024, trading 1,285 units of CMRX stock currently worth $1,067.

What does Chimerix Inc do?

led by an experienced antiviral drug development team, chimerix is developing novel oral antiviral therapeutics with the potential to improve quality of life for patients in multiple settings, including transplant, oncology, acute care and global health. the company’s proprietary lipid technology has given rise to two clinical stage compounds, cmx001 and cmx157, which have demonstrated the potential for enhanced activity, bioavailability and safety compared to currently approved drugs. chimerix’s lead compound, cmx001, is a broad spectrum lipid acyclic nucleoside phosphonate that inhibits double-stranded dna (dsdna) viruses including cytomegalovirus (cmv), adenovirus, bk virus, herpes simplex virus and variola (smallpox). cmx001 has completed phase 2 clinical development for the prophylaxis of cmv and is in phase 2 development for the preemption and treatment of adenovirus infection in hematopoietic stem cell transplant (hsct) recipients. to date, more than 750 patients have been dosed

Complete history of Ms. Demski stock trades at Adamas Pharmaceuticals Inc, Adma Biologics Inc, Chimerix Inc oraz Equillium Inc

Chimerix Inc executives and stock owners

Chimerix Inc executives and other stock owners filed with the SEC include:

• Michael Sherman,
  President, Chief Executive Officer, Director
• Michael Andriole,
  Chief Financial Officer, Chief Business Officer
• Michael Alrutz,
  Senior Vice President, General Counsel
• Michael A. Sherman,
  CEO, Pres & Director
• Michael T. Andriole M.B.A.,
  Chief Bus. Officer, Sec. & CFO
• Dr. Allen S. Melemed M.B.A., M.D.,
  Chief Medical Officer
• Martha Demski,
  Independent Chairman of the Board
• Patrick Machado,
  Independent Director
• Fred Middleton,
  Independent Director
• Robert Meyer,
  Independent Director
• Catherine Gilliss,
  Independent Director
• Edward Greissing,
  Independent Director
• Pratik Multani,
  Independent Director
• Dr. Joshua E. Allen,
  Chief Technology Officer of Imipridones
• Dr. Michael A. Alrutz,
  Sr. VP, Gen. Counsel & Corp. Sec.
• Michelle LaSpaluto,
  VP of Strategic Planning & Investor Relations
• Dr. Randall Lanier,
  Chief Science Officer
• Dr. Roy W. Ware,
  Chief Manufacturing & Technology Officer
• David Jakeman,
  Exec. Director of Fin. & Accounting and Principal Accounting Officer
• Michael D. Rogers,
  Chief Development Officer
• James Niedel,
  Director
• Ernest Mario,
  Director
• M Michelle Berrey,
  President and CEO
• Garrett Nichols,
  Chief Medical Officer
• John M Leonard,
  Director
• Ronald C Jr Renaud,
  Director
• James M Daly,
  Director
• Lisa Ricciardi,
  Director
• Timothy Wollaeger,
  Director
• Linda M Richardson,
  Chief Commercial Officer
• Ed Greissing,
  Director
• Victoria Vakiener,
  
• Leaf Ventures Ii, L.P. New,
  10% owner
• Venture Partners V, Lp Sand...,
  10% owner
• Venture Partners Vi Co Inve...,
  10% owner
• Rodman L Drake,
  Director
• Vii L P Canaan Partners Vii...,
  
• Leaf Ventures Ii, L.P.New L...,
  
• Kenneth I Moch,
  President and CEO
• Wende S Hutton,
  Director
• Venture Partners V, Lp Sand...,
  
• Arthur M Pappas,
  Director
• Venture Partners V, Lpsande...,
  
• Farah Champsi,
  Director
• Timothy W. Trost,
  SVP, CFO & Secretary
• Biopharma Partners Iii Lpal...,
  
• Pappas Life Science Venture...,
  
• Lisa Lynn Decker,
  
• Pharmaceuticals, Inc. Cantex,
  10% owner
• Marc D Kozin,
  
• David Jakeman,
  VP OF FINANCE AND ACCOUNTING
• Thomas J Riga,
  COO and CCO
• Allen S. Melemed,
  CHIEF MEDICAL OFFICER
• Michelle La Spaluto,
  CHIEF FINANCIAL OFFICER